WB results showed that compared with the AD and ADST group, the CTL group (vs. AD, Aβ42, F(1,16) = 141.876, GFAP, F(1,16) = 361.642, NF200, F(1,16) = 66.025; vs. ADST, Aβ42, F(1,16) = 153.697, GFAP, F(1,16) = 548.100, NF200, F(1,16) = 54.372; all P < 0.001) and ADT group (vs. AD, Aβ42, F(1,16) = 609.422, GFAP, F(1,16) = 174.968, NF200, F(1,16) = 78.230; vs. ADST, Aβ42, F(1,16) = 559.801, GFAP, F(1,16) = 253.792, NF200, F(1,16) = 57.307; all P < 0.001) exhibited significant differences in Aβ42, GFAP, and NF200 levels in the hippocampus. This evidence concerns the gene GFAP and Alzheimer disease.